The phase II randomized, non-comparative EFFORT trial reported the efficacy of adavosertib (WEE1 inhibitor) in PARP-resistant ovarian cancer with an objective response rate (ORR) of 29% in the combination adavosertib plus olaparib arm and 23% with adavosertib alone [87]. This evidence concerns the gene PARP1 and ovarian cancer.